{"id":"W3204380660","doi":"10.1016/j.jtho.2021.09.014","title":"IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; Genentech; Eisai; Daiichi-Sankyo; Mirati Therapeutics; Clovis Oncology; Johnson and Johnson; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Bayer; Gilead Sciences; Roche; Celgene; Novartis; Exelixis; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Incyte; Pfizer; Canadian Asian Studies Association; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Bevacizumab; Carboplatin; Hazard ratio; Internal medicine; Oncology; Paclitaxel; Chemotherapy; Confidence interval; Gastroenterology; Cancer; Nivolumab; Cisplatin; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009268543,0.002547444,0.003608212,0.001072748,0.0006930158,0.002166195,0.002715745,0.002065587,0.01857083],"category_scores_gemma":[0.03181639,0.0008392124,0.01444256,0.0008648629,0.0008182914,0.002910887,0.001963156,0.004467233,0.002144837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009574978,"about_ca_system_score_gemma":0.001392044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003709492,"about_ca_topic_score_gemma":0.006656397,"domain_scores_codex":[0.9907333,0.0047899,0.0004555004,0.001972083,0.0007174137,0.001331878],"domain_scores_gemma":[0.9831382,0.01282108,0.001083918,0.001780867,0.0004715612,0.0007042334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2335176,0.002332907,0.3737414,0.005842235,0.1579607,0.003994966,0.001402062,0.02210553,0.0160347,0.007988697,0.08470634,0.09037296],"study_design_scores_gemma":[0.02342718,0.04225994,0.6280764,0.001095042,0.09572225,0.004075864,0.002435789,0.08003,0.01220187,0.02700512,0.08298552,0.0006849772],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9098955,0.007339589,0.02308326,0.002532638,0.001663778,0.0009688322,0.04106756,0.0009429621,0.01250577],"genre_scores_gemma":[0.9694419,0.0003658206,0.006250668,0.001776075,0.0004590663,0.001206441,0.01058905,0.0006520362,0.009258937],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01857083,"threshold_uncertainty_score":0.06212562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09509215825979998,"score_gpt":0.4425816826641609,"score_spread":0.3474895244043609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}